Achieve Life Sciences (ACHV) Liabilities and Shareholders Equity (2016 - 2026)
Achieve Life Sciences (ACHV) has disclosed Liabilities and Shareholders Equity for 17 consecutive years, with $33.1 million as the latest value for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 21.01% to $33.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $185.9 million through Mar 2026, up 4.01% year-over-year, with the annual reading at $41.8 million for FY2025, 8.17% up from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 was $33.1 million at Achieve Life Sciences, down from $41.8 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $70.0 million in Q1 2024, with the low at $19.4 million in Q4 2023.
- Average Liabilities and Shareholders Equity over 5 years is $38.6 million, with a median of $34.0 million recorded in 2022.
- The sharpest move saw Liabilities and Shareholders Equity skyrocketed 236.71% in 2024, then crashed 60.93% in 2025.
- Achieve Life Sciences' Liabilities and Shareholders Equity stood at $30.0 million in 2022, then crashed by 35.37% to $19.4 million in 2023, then soared by 99.44% to $38.6 million in 2024, then increased by 8.17% to $41.8 million in 2025, then fell by 20.78% to $33.1 million in 2026.
- Per Business Quant, the three most recent readings for ACHV's Liabilities and Shareholders Equity are $33.1 million (Q1 2026), $41.8 million (Q4 2025), and $52.0 million (Q3 2025).